Literature DB >> 26815433

Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China.

W Ma1, J Sun1, S Yang1, L Zhang2.   

Abstract

Phenotypic heteroresistance (PHR) is common in a weight of microbes and plays an important role in the evolution of antibiotic resistance. However, PHR to cefepime (FEP-PHR) among invasive Escherichia coli (E. coli) has not been reported. This study aimed to report the characteristics of invasive E. coli with FEP-PHR traits and further to investigate the predisposing factors for its acquisition. A retrospective case-control study was conducted in a teaching hospital in Southwest China. A total of 319 successive and non-duplicate E. coli strains were isolated from blood and other sterile body fluids between July 2011 and August 2013. Among the seventy (70/319, 21.9 %) isolates harboring FEP-PHR traits, 30 (42.9 %) isolates were isolated from blood, 14 (20.0 %) isolates were isolated from bile, and 13 (18.6 %) isolates were isolated from drainage. FEP-PHR isolates were verified by population analysis profile (PAP) assays. Male gender, receipt of total parenteral nutrition, cephalosporins exposure, and production of extended spectrum betalactamases (ESBL) were independent risk factors for the acquisition of invasive E. coli with FEP-PHR traits. Pulsedfield gel electrophoresis (PFGE) revealed clonal diversity among the FEP-PHR isolates. The prevalence of heteroresistance to cefepime among invasive E. coli isolates merits great attention and heteroresistance may lead to the emergence of resistance strains. Therefore, systematical analysis of risk factors, careful interpretation of antibiotic susceptibility results and appropriate prescription of therapeutic strategy could help to prevent misreporting and therapeutic failure.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26815433     DOI: 10.1007/s10096-015-2572-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  25 in total

1.  Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.

Authors:  Carole Shubert; Jen Slaughter; David Creely; Alex van Belkum; Jean Pierre Gayral; William Michael Dunne; Gilles Zambardi; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Cefepime resistance and associated risk factors among Escherichia coli strains isolated from clinical specimens.

Authors:  Majid Mansouri; Rashid Ramazanzadeh; Parisa Norabadi
Journal:  Chemotherapy       Date:  2011-03-31       Impact factor: 2.544

4.  Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma.

Authors:  K A Kudsk; M A Croce; T C Fabian; G Minard; E A Tolley; H A Poret; M R Kuhl; R O Brown
Journal:  Ann Surg       Date:  1992-05       Impact factor: 12.969

Review 5.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 6.  ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.

Authors:  E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson
Journal:  Clin Microbiol Infect       Date:  2014-01       Impact factor: 8.067

7.  Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.

Authors:  H Kieft; A I Hoepelman; M Rozenberg-Arska; J M Branger; J H Voskuil; A B Geers; M Kluyver; H C Hart; E Poest-Clement; L van Beugen
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Characterization of carbapenemases, extended spectrum β-lactamases, quinolone resistance and aminoglycoside resistance determinants in carbapenem-non-susceptible Escherichia coli from a teaching hospital in Chongqing, Southwest China.

Authors:  Chuanming Zhang; Xiuyu Xu; Shuli Pu; Shifeng Huang; Jide Sun; Shuangshuang Yang; Liping Zhang
Journal:  Infect Genet Evol       Date:  2014-08-10       Impact factor: 3.342

9.  Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.

Authors:  Kayoko Hayakawa; Sureka Gattu; Dror Marchaim; Ashish Bhargava; Mohan Palla; Khaled Alshabani; Uma Mahesh Gudur; Harish Pulluru; Pradeep Bathina; Pranathi Rao Sundaragiri; Moumita Sarkar; Hari Kakarlapudi; Balaji Ramasamy; Priyanka Nanjireddy; Shah Mohin; Meenakshi Dasagi; Satya Datla; Vamsi Kuchipudi; Swetha Reddy; Shobha Shahani; Vijaya Upputuri; Satya Marrey; Vedavyas Gannamani; Nandhini Madhanagopal; Srinadh Annangi; Busani Sudha; Kalyan Srinivas Muppavarapu; Judy A Moshos; Paul R Lephart; Jason M Pogue; Karen Bush; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

10.  Heteroresistance at the single-cell level: adapting to antibiotic stress through a population-based strategy and growth-controlled interphenotypic coordination.

Authors:  Xiaorong Wang; Yu Kang; Chunxiong Luo; Tong Zhao; Lin Liu; Xiangdan Jiang; Rongrong Fu; Shuchang An; Jichao Chen; Ning Jiang; Lufeng Ren; Qi Wang; J Kenneth Baillie; Zhancheng Gao; Jun Yu
Journal:  MBio       Date:  2014-02-11       Impact factor: 7.867

View more
  4 in total

1.  Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.

Authors:  Ángel Rodríguez-Villodres; José Manuel Ortiz de la Rosa; Rocío Álvarez-Marín; Jerónimo Pachón; Javier Aznar; José Antonio Lepe; Younes Smani
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  Mechanisms and clinical relevance of bacterial heteroresistance.

Authors:  Dan I Andersson; Hervé Nicoloff; Karin Hjort
Journal:  Nat Rev Microbiol       Date:  2019-06-24       Impact factor: 60.633

3.  Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Yu Bin Seo; Jacob Lee; Young Keun Kim; Seung Soon Lee; Jeong-A Lee; Hyo Youl Kim; Young Uh; Han-Sung Kim; Wonkeun Song
Journal:  BMC Infect Dis       Date:  2017-06-07       Impact factor: 3.090

4.  Characterization of Integrons and Antimicrobial Resistance in Escherichia coli Sequence Type 131 Isolates.

Authors:  Jiangqing Huang; Fangjun Lan; Yanfang Lu; Bin Li
Journal:  Can J Infect Dis Med Microbiol       Date:  2020-02-24       Impact factor: 2.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.